Sankar Chatterjee

USPTO Granted Patents = 42 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 3)

Average Co-Inventor Count = 3.3

ph-index = 11

Forward Citations = 298(Granted Patents)

Company Filing History:

Smithkline Beecham Corporation

patents

4. 1 out of 850

Millennium Pharmaceuticals Limited

where one patent can have more than one assignee

Years Active: 1996-2016

Loading Chart...

42 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9233115 - Proteasome inhibitors and methods of using the same (2016-01-12),

2. 8716493 - Multicyclic compounds and the use thereof (2014-05-06),

3. 8673916 - [object Object] (2014-03-18),

4. 8648067 - [object Object] (2014-02-11),

5. 8586588 - Aryl pyridazinone derivatives and their use as H3 receptor ligands (2013-11-19),

6. 8546608 - Proteasome inhibitors and methods of using the same (2013-10-01),

7. 8471005 - Pyrrolotriazines as ALK and JAK2 inhibitors (2013-06-25),

8. 8314155 - Bicyclic aromatic sulfinyl derivatives (2012-11-20),

9. 8247414 - Pyridizinone derivatives and the use thereof as H3 inhibitors (2012-08-21),

10. 8153667 - Tricyclic aromatic and bis-phenyl sulfinyl derivatives (2012-04-10),

11. 8058262 - Proteasome inhibitors and methods of using the same (2011-11-15),

12. 7981907 - Thio-substituted biarylmethanesulfinyl derivatives (2011-07-19),

13. 7915236 - Proteasome inhibitors and methods of using the same (2011-03-29),

14. 7449481 - Thio-substituted biaryl-methanesulfinyl derivatives (2008-11-11),

15. 7423176 - Bicyclic aromatic sulfinyl derivatives (2008-09-09),

**Title: Innovations and Patents of Sankar Chatterjee**

Introduction

Sankar Chatterjee, based in Wynnewood, PA, has made significant contributions to the field of science and medicine through his extensive work as an inventor. With a remarkable portfolio of 42 patents, he has dedicated his career to developing innovative solutions for complex health issues, particularly in oncology and neurodegenerative diseases.

Latest Patents

Sankar Chatterjee's latest patents include:

1. **Proteasome Inhibitors and Methods of Using the Same**

This invention provides boronic acid compounds and boronic esters that modulate apoptosis by inhibiting proteasome activity. These novel compounds can be utilized in methods for inducing apoptosis and treating various diseases such as cancer, along with other disorders directly or indirectly associated with proteasome activity.

2. **Multicyclic Compounds and the Use Thereof**

This patent focuses on innovative multicyclic molecules that mediate enzymatic activity. The compounds are notably effective in addressing diseases related to PARP, VEGFR2, and MLK3 enzyme activities. These include neurodegenerative diseases, inflammation, ischemia, and cancer.

Career Highlights

Throughout his career, Sankar Chatterjee has been associated with notable companies in the pharmaceutical sector, including Cephalon, Inc. and Cephalon France. His work has been pivotal in advancing research and development in therapeutic solutions.

Collaborations

Sankar Chatterjee has collaborated with esteemed professionals such as Derek D. Dunn and Edward R. Bacon. These collaborations have enhanced the scope and impact of his inventions, promoting advancements in the field of medicinal chemistry.

Conclusion

Sankar Chatterjee's dedication to innovation and patent development has marked him as a significant figure in the realm of medicinal inventions. His contributions in the form of numerous patents reflect a commitment to addressing critical health challenges, particularly through the modulation of enzymatic activity and apoptosis in treating serious diseases. His work continues to inspire advancements in pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.